Latest Insider Transactions at Keros Therapeutics, Inc. (KROS)
This section provides a real-time view of insider transactions for Keros Therapeutics, Inc. (KROS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Keros Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Keros Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
10,711
-0.2%
|
$631,949
$59.88 P/Share
|
|
Mar 01
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
12,979
-0.17%
|
$830,656
$64.24 P/Share
|
|
Feb 26
2021
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,200
+35.17%
|
$0
$0.11 P/Share
|
|
Feb 18
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
2,944
-0.05%
|
$182,528
$62.79 P/Share
|
|
Feb 17
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
16,061
-0.29%
|
$963,660
$60.78 P/Share
|
|
Feb 16
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
9,612
-0.21%
|
$567,108
$59.74 P/Share
|
|
Feb 12
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
7,468
-0.13%
|
$463,016
$62.15 P/Share
|
|
Feb 11
2021
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,300
-2.82%
|
$344,500
$65.44 P/Share
|
|
Feb 11
2021
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+13.73%
|
$0
$0.3 P/Share
|
|
Feb 11
2021
|
Claudia Ordonez Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,000
-59.35%
|
$65,000
$65.37 P/Share
|
|
Feb 11
2021
|
Claudia Ordonez Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+50.0%
|
$0
$0.48 P/Share
|
|
Feb 11
2021
|
Julius Knowles |
SELL
Open market or private sale
|
Indirect |
11,561
-0.17%
|
$751,465
$65.32 P/Share
|
|
Nov 17
2020
|
Pontifax Management 4 G.P. (2015) Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
60,000
+1.79%
|
$3,000,000
$50.0 P/Share
|
|
Nov 17
2020
|
Tomer Kariv |
BUY
Open market or private purchase
|
Indirect |
60,000
+1.79%
|
$3,000,000
$50.0 P/Share
|
|
Nov 17
2020
|
Ran Nussbaum |
BUY
Open market or private purchase
|
Indirect |
60,000
+1.79%
|
$3,000,000
$50.0 P/Share
|
|
Apr 13
2020
|
Julius Knowles |
BUY
Open market or private purchase
|
Direct |
1,191
+50.0%
|
$23,820
$20.98 P/Share
|
|
Apr 13
2020
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
375,200
+25.1%
|
$6,003,200
$16.0 P/Share
|
|
Apr 13
2020
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
893,534
+50.0%
|
-
|